Glucose‐6‐phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine
G6PD deficiency is associated with higher response rates and improved survival in patients with ND-AML treated with Ven-Aza. These findings support G6PD deficiency as a potential biomarker of therapeutic sensitivity to Ven-AZA and may uncover metabolic vulnerabilities in AML with potential therapeutic implications.
Authors
- Ofir Wolach (ORCID: https://orcid.org/0000-0002-8662-0707)
- Galit Granot (ORCID: https://orcid.org/0000-0002-3377-6521)
- P. Raanani
- Shirly Partouche
- Shira Buchrits (ORCID: https://orcid.org/0000-0002-1034-8583)
- Alon Rozental (ORCID: https://orcid.org/0000-0001-7339-5494)
- Ofer Algor
- Noa Korngold
Institutions
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Cancer
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1002/cncr.70265
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00